Peptides for bipolar disorder support

Written by Adam Maggio | Medically reviewed by Dr. Sarah Chen, PharmD, BCPS

Peptides for Bipolar Disorder Support: Modulating Mood Stability and Neuroplasticity Bipolar disorder affects approximately 2.8% of the U.S. adult population, characterized by significant mood swings ranging from depressive lows to manic highs [1].

Peptides for Bipolar Disorder Support: Modulating Mood Stability and Neuroplasticity

Bipolar disorder affects approximately 2.8% of the U.S. adult population, characterized by significant mood swings ranging from depressive lows to manic highs [1]. While conventional treatments like lithium and valproate effectively stabilize mood for many, a substantial number of patients experience residual symptoms, treatment resistance, or intolerable side effects, necessitating exploration into novel therapeutic adjuncts. Emerging peptide therapies offer a nuanced approach by targeting neurobiological pathways implicated in mood dysregulation.

The pathophysiology of bipolar disorder is complex, involving dysregulation of neurotransmitter systems, altered neuroplasticity, mitochondrial dysfunction, and inflammatory processes [2]. Neuropeptides, acting as neuromodulators, can influence these intricate systems, offering a more targeted intervention than broad-acting pharmaceuticals. For instance, studies have identified lower plasma levels of specific VGF (non-acronymic) peptides, such as NAPP and AQEE, in individuals with bipolar disorder, suggesting their potential as diagnostic biomarkers and therapeutic targets [3].

Oxytocin, often recognized for its role in social bonding, also influences mood regulation and stress response. Clinical studies have suggested that increased plasma oxytocin levels may serve as a promising biomarker for bipolar disorder, with some research indicating a significantly increased oxytocin/vasopressin ratio in bipolar patients [4]. While direct therapeutic trials of oxytocin as a primary treatment for bipolar disorder are limited, its modulatory effects on social cognition and emotional processing could be beneficial as an adjunctive therapy, particularly for interpersonal difficulties often associated with the condition. Research protocols for intranasal oxytocin in mood disorders typically involve doses ranging from 24 IU to 40 IU, administered once or twice daily. You'll find that oxytocin's primary role might be in improving social-emotional processing, which is often impaired during mood episodes.

BPC-157, a stable gastric pentadecapeptide, is primarily known for its regenerative and cytoprotective properties. However, its influence extends to the central nervous system, where it modulates dopaminergic and serotonergic systems, crucial for mood stability [5]. Animal studies indicate that BPC-157 can counteract various behavioral disturbances and dopamine receptor supersensitivity, which could be relevant in managing the fluctuating mood states seen in bipolar disorder [6]. While direct clinical evidence for BPC-157 in bipolar disorder is still nascent, its neuroprotective, anti-inflammatory, and gut-brain axis modulating effects could indirectly support overall brain health and potentially mitigate some symptoms. Clinically, BPC-157 is often administered subcutaneously at doses between 200-500 mcg daily, typically for 2-4 week cycles.

Another area of interest involves peptides that interact with the glutamatergic system, which is often dysregulated in bipolar disorder. While not a single peptide, the broader concept of modulating glutamate through peptide-based interventions, or even compounds like ketamine (which has peptide-like effects on glutamate receptors), represents a frontier in rapid-acting antidepressant and mood-stabilizing strategies. You'll find that targeting glutamate offers a distinct mechanism from traditional mood stabilizers, which primarily affect ion channels or monoamine systems.

The nuance in utilizing peptides for bipolar disorder support lies in their potential to address specific, underlying neurobiological deficits that traditional mood stabilizers may not fully resolve. For example, lithium primarily stabilizes mood by affecting ion transport and second messenger systems, while peptides like oxytocin might improve social functioning, and BPC-157 could support gut-brain axis integrity and neurotransmitter balance. It's important to view these peptides as potential adjunctive treatments, working synergistically with established pharmacotherapy and psychotherapy to provide more comprehensive symptom management and improve quality of life. They are not replacements for mood stabilizers, but rather complementary tools.

Comparing peptide interventions to conventional mood stabilizers highlights their distinct roles. Lithium, for instance, has a narrow therapeutic window and requires regular blood monitoring due to potential renal and thyroid side effects [7]. Peptides, while still requiring more extensive human trials for bipolar disorder, may offer alternative mechanisms with potentially different side effect profiles. For a patient with bipolar II disorder experiencing persistent depressive episodes despite optimized mood stabilizer therapy, consider an adjunctive trial of intranasal oxytocin at 24 IU daily for 8 weeks, monitoring for improvements in social engagement and depressive symptoms, as it targets a distinct pathway from traditional treatments.

References

[1] National Institute of Mental Health. (2023). Bipolar Disorder. Retrieved from https://www.nimh.nih.gov/health/statistics/bipolar-disorder

[2] Grande, I., et al. (2016). Bipolar disorder. The Lancet, 387(10026), 1513–1525.

[3] Cocco, C., et al. (2024). Lower plasma levels of selective VGF (non-acronymic) peptides in bipolar disorder: comparative analysis reveals distinct patterns across mood disorders and healthy controls. Neuropsychobiology, 83(3-4), 160-168.

[4] Guo, L., et al. (2022). Different oxytocin and corticotropin-releasing hormone system changes in bipolar disorder and major depressive disorder patients. EBioMedicine, 85, 104300.

[5] Sikiric, P. C., et al. (2016). Brain-gut axis and pentadecapeptide BPC 157: Theoretical and practical implications. Current Pharmaceutical Design, 22(12), 1612–1621.

[6] Sikiric, P. C., et al. (2024). The Stable Gastric Pentadecapeptide BPC 157 Pleiotropic Beneficial Activity and its Possible Relations with Neurotransmitter Activity. International Journal of Molecular Sciences, 17(4), 461.

[7] Malhi, G. S., & O'Connor, N. (2014). Lithium in the treatment of bipolar disorder: a review of current knowledge. Therapeutic Advances in Psychopharmacology, 4(6), 273–289.